CD274 and hepatocellular carcinoma: Immune checkpoint inhibitors (ICI) have been a recent development in HCC treatment and the IMbrave 150 trial showed that atezolizumab (anti-programmable death ligand 1 (PDL1)) and bevacizumab (anti-VEGF) are an effective treatment for HCC [119].